GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 1,266 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,266 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $53.77, for a total value of $68,072.82. Following the transaction, the chief financial officer directly owned 36,486 shares of the company’s stock, valued at approximately $1,961,852.22. The trade was a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total value of $25,554.48.
• On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total value of $438,220.80.

GeneDx Stock Up 12.3%

Shares of WGS opened at $60.99 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -22.76 and a beta of 1.96. The stock has a 50 day moving average price of $55.07 and a 200 day moving average price of $90.41.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. Equities research analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on WGS. BTIG Research dropped their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price target on GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Piper Sandler reiterated an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Reports that hedge fund manager Eli Casdin is buying more GeneDx shares could be viewed as a vote of confidence in the company’s long-term value. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Multiple law firms continue to publicize an already-filed securities class action and the August 3, 2026 lead-plaintiff deadline. These updates mostly keep the case in focus rather than adding new operational news. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional notices from Rosen, Faruqi & Faruqi, Schall, Robbins LLP, and other firms reinforce the litigation backdrop around alleged misstatements tied to the Fabric Genomics acquisition and Q1 2026 results. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: CEO Katherine Stueland sold 3,639 shares and CFO Kevin Feeley sold 1,266 shares on June 9. GeneDx said the transactions were to cover tax withholding tied to vesting equity awards, but insider sales can still weigh on investor sentiment. CEO Form 4 Filing
• Negative Sentiment: The class action claims GeneDx misled investors about reimbursement rates, margin compression, and the impact of the Fabric Genomics acquisition, creating a continuing legal and reputational overhang. GeneDx Holdings (WGS) Faces Securities Class Action…

Institutional Trading of GeneDx

Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in GeneDx by 77.5% in the 1st quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock valued at $15,066,000 after buying an additional 102,456 shares in the last quarter. California State Teachers Retirement System grew its holdings in GeneDx by 31.2% in the 1st quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after buying an additional 5,951 shares in the last quarter. Ashford Capital Management Inc. grew its holdings in GeneDx by 31.9% in the 1st quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after buying an additional 42,186 shares in the last quarter. Quantinno Capital Management LP grew its holdings in GeneDx by 99.2% in the 1st quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock valued at $245,000 after buying an additional 1,897 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new stake in GeneDx in the 1st quarter valued at $15,601,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.